What medicines should not be taken with resmetirom?

Resmetirom-Rezdiffra shows good promise in the treatment of NASH, but drug-drug interactions cannot be ignored in clinical use. Its metabolic pathway mainly involves the liver enzyme system, so taking some drugs at the same time may affect their blood concentration, increase adverse reactions or reduce efficacy. According to overseas drug information, it is not recommended to use rismetirol simultaneously with drugs that strongly inhibit or induce CYP3A enzyme. For example, some antifungal drugs, some antiepileptic drugs, and some antiviral drugs will either significantly increase the blood concentration of rismetirol and increase the risk of adverse reactions, or they will accelerate its metabolism, resulting in insufficient drug efficacy.

Another class of drugs worth noting are those containing strong cholesterol-modulating effects, such as high-dose statins. Although statins themselves are not uncommon in NASH patients, they may have pharmacokinetic interactions with rismetirol, leading to an increased risk of myotoxicity or abnormal liver function. Therefore, in clinical practice, doctors often adjust the dosage or replace alternative drugs based on individual circumstances.

In addition, certain drugs used to treat cardiac arrhythmias or immunosuppression also need to be used with caution because they share some metabolic pathways with resmetirol or produce competitive metabolism in the body. For patients who require long-term multi-drug combination therapy, doctors usually conduct a detailed assessment of past medication history before prescribing resmetirol to avoid drug interactions.

From the patient's perspective, do not use risimeterol in combination with other drugs, especially common health products and herbal supplements. Some may also indirectly affect the stability of risimeteiro through liver metabolism channels. In general, resmetiro needs to be cautious in terms of drug interactions and avoid co-use with strong CYP3A inhibitors, inducers and high-risk metabolizing drugs.

Reference materials:https://www.drugs.com/monograph/resmetirom.html